Jobs
-
Hovione has announced the filing of an international patent for its new XCaps dry powder inhaler. According to the company, the XCaps DPI is “a device which only requires two steps to inhalation and which… Read more . . .
-
Sun Pharma Advanced Research Company (SPARC) has announced completion of Phase 3 studies for a new dry powder inhaler and its intention to launch a product based on the novel DPI in India by the… Read more . . .
-
Dry powder inhalation drug developer Savara Pharmaceuticals has graduated from the Austin Techonology Incubator (ATI) Bioscience Incubator, according to ATI. Savara, which was founded in 2007, is preparing for Phase 1 trials of its lead… Read more . . .
-
The Walter and Eliza Hall Institute (WEHI), Melbourne, Australia, has announced successful demonstration of proof of principle for a nasal spray vaccine to prevent type 1 diabetes. The research, conducted by scientists from WEHI and… Read more . . .
-
At the European Cystic Fibrosis Conference in Hamburg, Germany, Insmed presented data showing that Arikace liposomal amikacin for inhalation improved lung function in CF patients over six cycles of treatment. Each cycle included 28 days… Read more . . .
-
GlaxoSmithKline plans to expand its manufacturing facility in Mississauga, Ontario, in part to enable production of Relenza zanamivir dry powder for inhalation. The expansion is expected to create 70 new jobs. GSK will contribute more… Read more . . .
-
Respira Therapeutics has issued a press release to introduce its drug engine technology (DET) dry powder inhaler, which the company says “can be deployed and optimized in short test cycles with a wide range of… Read more . . .
-
University of Melbourne spin-off Otifex has reportedly raised $1.1 million for the development of a nasal spray to treat otitis media with effusion (OTE), in which viscous fluid builds up in the middle ear, potentially… Read more . . .
-
The US FDA has granted orphan drug designation to Aradigm Corporation’s dual release ciprofloxacin for inhalation (DRCFI) for the treatment of bronchiectasis. The company’s liposomal ciprofloxacin for inhalation (CFI) already has orphan drug designation from… Read more . . .
-
Reuters is reporting that the Swedish Medical Products Agency has approved a fluticasone/salmeterol DPI manufactured by Greek pharmaceutical company Elpen. The approval apparently took place in May 2011 but was not announced. The company has… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland